GSK plc announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with Shingrix (Recombinant Zoster Vaccine or RZV)
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...
Herpes zoster (HZ), also known as shingles, results from reactivation of the latent varicella-zoster virus (VZV), which commonly causes chickenpox in childhood. Greater than 90% of adults are infected with this virus, putting them at risk for reactivation.
GlaxoSmithKline plc announced that the second pivotal phase III study of its candidate vaccine Shingrix in adults aged 70 years...
GlaxoSmithKline announced that the European Commission has approved Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia (PHN)...
GlaxoSmithKline announced the regulatory submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for...
GlaxoSmithKline announced that it has submitted a Biologics License Application (BLA) for its candidate shingles vaccine, Shingrix, to the FDA,...
GlaxoSmithKline will be presenting new results from a clinical study showing that its candidate vaccine for the prevention of herpes...
GSK plc announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are at increased risk.
GlaxoSmithKline has announced new data for its shingles candidate vaccine Shingrix, examining co-administration of GSK's candidate vaccine with the flu...